Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

JNJJanssen Research & Development, LLCRunning, no new patients

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Neoplasms

12Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Nov 2023, none posted yet

    Counts until it's fixed

    +10

  • 4 insiders sold shares within a month

    Since Aug 17, 2026 · was worth 5, fading over time

    +2
Worry score12

Score over time

Stage
Phase 1/2
Patients
234 (final count)
Started
Nov 21, 2016
Main results expected
Nov 17, 2023
Fully finished
Dec 31, 2026
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1: Frequency and Severity of Dose-Limiting Toxicity (DLT)

    Measured over: Up to 2 years 6 months

  • Part 2: Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Subjects With Selected Advanced Solid Tumors

    Measured over: Up to 2 years 6 months

  • Parts 3 and 4: Area Under the Serum Concentration Versus Time Curve from Time Zero to Dosing Interval (AUC [0-tau])

    Measured over: Up to 2 years 6 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2023-11-17, no fading
  • insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT02908906 · record last updated 2026-08-31 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT02908906) ↗